Significant improvement of dermatitis herpetiformis with tofacitinib

We present a patient treated with tofacitinib, 5mg twice daily, an oral JAK1/3 inhibitor, who demonstrated clinical improvement of DH and control of new lesion development.PMID:34391330 | DOI:10.5070/D327754365

Source: Dermatol Online J - August 15, 2021 Category: Dermatology Authors: Jared S Kahn Katherine Moody David Rosmarin Source Type: research